Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Enzo Biochem ( (ENZB) ) just unveiled an announcement.
Enzo Biochem has completed a merger that resulted in significant changes to its corporate structure and stock status. As of August 20, 2025, the company’s common stock ceased trading on the OTCQX market, and the company plans to deregister its stock with the SEC. The merger led to the cancellation of outstanding shares, restricted stock units, options, and warrants, with certain stakeholders receiving cash considerations. Additionally, several directors stepped down, and the company’s certificate of incorporation and bylaws were amended in accordance with the merger agreement.
The most recent analyst rating on (ENZB) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Enzo Biochem stock, see the ENZB Stock Forecast page.
Spark’s Take on ENZB Stock
According to Spark, TipRanks’ AI Analyst, ENZB is a Neutral.
Enzo Biochem’s overall stock score is primarily impacted by its challenging financial performance and valuation issues due to declining revenues and profitability. However, the upcoming merger with Battery Ventures provides a positive outlook, offering a significant premium and a strategic path forward. Technical analysis shows potential short-term gains but also warns of overbought conditions.
To see Spark’s full report on ENZB stock, click here.
More about Enzo Biochem
Average Trading Volume: 368,864
Technical Sentiment Signal: Sell
Current Market Cap: $35.99M
For an in-depth examination of ENZB stock, go to TipRanks’ Overview page.